Physician Views: As it edges towards market we survey cardiologists about inclisiran

Twelve months on from announcing its acquisition of The Medicines Company for $9.7 billion, Novartis is awaiting US and European approval for the former's flagship asset; the RNAi-based PCSK9 inhibitor inclisiran.

Dosed just twice a year, inclisiran has been shown to reduce LDL cholesterol levels by up to 52% when added to standard-of-care therapy. Novartis has described the drug as a potentially transformative medicine and at an investor event on Tuesday said that it anticipates global sales of inclisiran reaching $1.4 billion by 2025. By this point, the read out of further clinical data potentially showing a positive effect on cardiovascular outcomes could boost revenues further.

Expert opinion - KOL Views Results: Detailed ORION-11 data tick a lot of boxes for inclisiran, according to leading expert

Ahead of pending regulatory decisions, we are running a short survey to US and European (France, Italy, Germany, Spain and the UK) cardiologists to gauge sentiment towards inclisiran ahead of potential launch…

Q. Inclisiran, an investigational siRNA LDL cholesterol lowering treatment, is awaiting regulatory approval in the US and Europe for atherosclerotic cardiovascular disease. Are you aware of this product and the clinical data that has been presented for it?

No

Yes

Yes, and I am eager to use inclisiran

__________

Q. When added to standard-of-care treatment, inclisiran has been shown to deliver an effective and sustained LDL cholesterol reduction of up to 52% when administered twice a year by injection and has been shown to be well tolerated with a safety profile comparable to placebo, except for injection-site reactions.

How do you perceive the clinical innovation of this therapy versus current standard-of-care therapies?

1 – None             2            3            4 – Moderate    5            6            7 – Very high

__________

Q. Thinking about efficacy, adherence benefits and potential longer-term improvements in cardiovascular outcomes (with data pending and expected in 2025), how would you rate inclisiran as meeting an unmet clinical need?

1 – None             2            3            4 – Moderate    5            6            7 – Very high

__________

Q. How would you rate your likelihood of using inclisiran if it is approved?

1 – None             2            3            4 – Moderate    5            6            7 – Very high

__________

Q. If subsequent data show that inclisiran improves cardiovascular outcomes, what impact will this have on your use?

1 – None             2            3            4 – Moderate    5            6            7 – Very high

__________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here

To read more Physician Views articles, click here.